INBRX-106 is under clinical development by Inhibrx and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III drugs for Oropharyngeal Cancer have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how INBRX-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INBRX-106 overview
INBRX-106 is under development for the treatment of solid tumors including non-small cell lung cancer, uveal melanoma, esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer, head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer, gastrointestinal stromal tumor, gastric or gastro-esophageal junction adenocarcinoma, nasopharyngeal cancer, renal cell carcinoma, nasopharyngeal cancer, cervical cancer, gastrointestinal tumor, urothelial (transitional) cell carcinoma, triple-negative breast cancer, small cell lung cancer and hematological malignancies. The drug candidate is an optimized, single domain antibody (sdAb)-based hexavalent agonist of OX40.The drug candidate is a multivalent constitutive agonist. It acts by targeting the OX40 ligand. The drug candidate is developed based on a single domain antibody (sdAb) platform.
Inhibrx overview
Inhibrx is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating the INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1 (PD-L1) expressing tumors. It utilizes its proprietary sdAb (single-domain antibody) platform to develop biotherapeutics that interface with the biology of each target antigen by focusing on immune activation and mediating enhanced signaling. Inhibrx is headquartered in La Jolla, California, the US.
For a complete picture of INBRX-106’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
